Drug Use Following Genetic Testing Among Patients with Cancer

Project Title Drug Use Following Genetic Testing Among Patients with Cancer
Date Posted
Wednesday, May 10, 2017
Project ID
cder_mpl1r_wp021-23_nsdp_v01
Status
Complete
Deliverables
Description

This project contains three reports. Report 1 contains estimates of drug use among patients with a prior genetic test and/or relevant cancer diagnosis. Report 2 contains estimated distribution of baseline covariates among members receiving various genetic tests: KRAS, BRAF, EGFR, BCR-ABL, and BRCA. Report 3 contains estimates of drug initiation following genetic testing among patients with relevant cancers.The query was run against the Sentinel Distributed Database (SDD) for the time period of January 1, 2013 to December 31, 2015. The request was distributed to 14 Data Partners on June 17, 2016.

Medical Product
BCR-ABL
BRAF
BRCA
KRAS
afatinib dimaleate
bosutinib
cetuximab
cobimetinib fumarate
dabrafenib mesylate
dasatinib
erlotinib HCL
estimated glomerular filtration rate (eGFR)
gefitinib
imatinib mesylate
nilotinib HCL
olaparib
osimertinib mesylate
panitumumab
ponatinib HCL
trametinib dimethyl sulfoxide
vemurafenib
Health Outcome
cancer
Population / Cohort
All individuals
Time Period
January 1, 2013 - December 31, 2015
Assessment Type
Exploratory Analyses
Study Type
Modular Program
Data Sources
Sentinel Distributed Database (SDD)
FDA Center
CDER
Scroll to Top